HB Wealth Management LLC raised its holdings in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 44.7% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 46,563 shares of the company's stock after purchasing an additional 14,390 shares during the period. HB Wealth Management LLC's holdings in AstraZeneca were worth $3,422,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors also recently added to or reduced their stakes in the company. Banque Transatlantique SA bought a new stake in AstraZeneca during the 4th quarter worth approximately $26,000. Confluence Investment Management LLC bought a new stake in AstraZeneca during the 1st quarter worth approximately $27,000. Larson Financial Group LLC increased its stake in AstraZeneca by 297.9% during the 1st quarter. Larson Financial Group LLC now owns 386 shares of the company's stock worth $28,000 after purchasing an additional 289 shares in the last quarter. Mascagni Wealth Management Inc. bought a new stake in AstraZeneca during the 4th quarter worth approximately $29,000. Finally, FNY Investment Advisers LLC bought a new stake in AstraZeneca during the 1st quarter worth approximately $29,000. 20.35% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
AZN has been the subject of several research reports. Berenberg Bank set a $97.00 price target on shares of AstraZeneca in a research note on Wednesday, July 9th. BNP Paribas initiated coverage on shares of AstraZeneca in a research note on Tuesday, April 15th. They set an "outperform" rating and a $75.00 price target for the company. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $89.00.
Check Out Our Latest Stock Analysis on AZN
AstraZeneca Stock Down 2.0%
Shares of AZN traded down $1.50 during mid-day trading on Thursday, hitting $75.09. 4,670,093 shares of the company's stock were exchanged, compared to its average volume of 5,365,045. AstraZeneca PLC has a 52 week low of $61.24 and a 52 week high of $87.68. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.90 and a quick ratio of 0.70. The company has a 50-day simple moving average of $71.42 and a 200 day simple moving average of $71.26. The company has a market cap of $232.87 billion, a PE ratio of 28.23, a P/E/G ratio of 1.36 and a beta of 0.37.
AstraZeneca (NASDAQ:AZN - Get Free Report) last released its earnings results on Tuesday, July 29th. The company reported $1.09 earnings per share for the quarter, meeting the consensus estimate of $1.09. AstraZeneca had a net margin of 14.68% and a return on equity of 33.61%. The business had revenue of $14.46 billion during the quarter, compared to analysts' expectations of $14.08 billion. During the same period last year, the business earned $1.24 earnings per share. The firm's revenue was up 16.1% on a year-over-year basis. On average, research analysts forecast that AstraZeneca PLC will post 4.51 earnings per share for the current fiscal year.
AstraZeneca Cuts Dividend
The company also recently announced a semi-annual dividend, which will be paid on Monday, September 8th. Investors of record on Friday, August 8th will be paid a $0.505 dividend. The ex-dividend date of this dividend is Friday, August 8th. This represents a dividend yield of 2%. AstraZeneca's dividend payout ratio is presently 82.73%.
About AstraZeneca
(
Free Report)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Featured Articles
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
